Vitamin K is given to newborns to prevent a rare but dangerous bleeding condition called vitamin K deficiency bleeding (VKDB). All babies are born with very low levels of vitamin K, a nutrient essential for blood clotting, and without supplementation, some will experience uncontrolled bleeding that can cause brain damage or death. A single shot given shortly after birth virtually eliminates this risk.
Why Newborns Have So Little Vitamin K
Vitamin K doesn’t cross the placenta efficiently. Research published in The Lancet found that even when mothers had normal vitamin K levels at delivery, the nutrient was undetectable in their babies’ cord blood. When researchers gave mothers a large intravenous dose of vitamin K right before delivery, only four out of six babies had any measurable amount, and those levels were still extremely low. The placenta simply doesn’t transfer this nutrient well.
After birth, babies don’t get much vitamin K through feeding either. Breast milk contains only about 1 to 9 micrograms of vitamin K per liter. Formula is fortified to about 55 micrograms per liter, which is why VKDB occurs almost exclusively in breastfed infants who didn’t receive the shot. Newborns also have sterile guts at birth, meaning they lack the intestinal bacteria that help produce vitamin K later in life. These factors combine to leave babies vulnerable during their first weeks and months.
What Vitamin K Does in the Body
Your body needs vitamin K to activate four key clotting factors in the blood. Without enough vitamin K, the body produces incomplete versions of these proteins that can’t bind calcium and can’t participate in clot formation. This means that when bleeding starts, whether from normal events like a circumcision or from something internal, the body can’t stop it effectively. Vitamin K also activates proteins C and S, which regulate the clotting process to prevent it from going too far in the other direction.
Three Types of Vitamin K Deficiency Bleeding
VKDB shows up in three distinct windows, each with different severity and causes.
Early-Onset VKDB (First 24 Hours)
This form appears within the first day of life and is almost always linked to medications the mother took during pregnancy, such as blood thinners or certain anti-seizure drugs. It tends to cause bleeding in the skull and brain, and outcomes are severe. In documented cases, intracranial hemorrhage was the most common feature, with the majority of affected infants suffering serious neurological damage.
Classic VKDB (Days 2 Through 7)
The classic form appears in the first week, often triggered by low vitamin K in breast milk and poor early feeding. Bleeding typically occurs in the gastrointestinal tract, from the umbilical stump, from the nose, or at circumcision sites. This form generally has a good prognosis because the bleeding tends to happen in locations where it can be identified and managed quickly.
Late-Onset VKDB (2 Weeks to 6 Months)
Late-onset VKDB is the most dangerous form. It strikes between 2 and 12 weeks of age, sometimes as late as 6 months. About 50% of late-onset cases in Western countries present as intracranial hemorrhage, with rates reaching 82% in developing countries. Mortality ranges from 20% to 50%, and among survivors of brain bleeding, a significant portion have lasting neurological damage. One study of infants admitted to intensive care for vitamin K-related brain hemorrhage found that 38% died and another 38% had severe neurological problems at six months of follow-up. Underlying liver or digestive conditions sometimes contribute, but many cases occur in otherwise healthy breastfed babies who simply didn’t receive prophylaxis.
How Effective the Shot Is
Without the vitamin K shot, roughly 0.25% to 1.7% of newborns will develop early or classic VKDB. Babies who skip the shot are 81 times more likely to develop late-onset VKDB compared to those who receive it. Widespread use of the injection has reduced the incidence of late VKDB by up to 98%. Since the American Academy of Pediatrics began recommending the shot in 1961, VKDB has been nearly eliminated in the United States.
What the Shot Involves
The standard practice is a single intramuscular injection of phytonadione (the synthetic form of vitamin K1) given within the first six hours after birth. Babies weighing more than about 3.3 pounds receive a 1.0 mg dose; smaller or premature infants receive 0.5 mg. The injection goes into the thigh muscle. It’s a one-time shot that provides enough vitamin K to protect the baby through the vulnerable period while their gut bacteria develop and their diet begins supplying adequate amounts.
Side effects are minimal. The most common reaction is brief discomfort at the injection site. In rare cases, particularly with doses higher than recommended, mild jaundice has been reported in newborns. Severe allergic reactions have been documented but are associated primarily with intravenous administration, which is not how the newborn shot is given.
Oral Vitamin K as an Alternative
Some parents ask about oral vitamin K drops instead of the injection. Several European countries have used oral regimens involving multiple doses given over weeks or months. These regimens vary widely: some involve three doses given at birth, around one week, and at four weeks. Others require daily or weekly drops for the first three months.
All oral regimens are less effective than the single injection. Studies of oral prophylaxis still show VKDB rates of up to 2.8 per 100,000 births, while the shot brings rates close to zero. Oral vitamin K is not approved by the FDA for VKDB prevention in the United States and is not routinely used there. The main limitation is that oral doses are absorbed less reliably, and the protection depends on parents completing every scheduled dose over several weeks. For families who decline the injection, oral vitamin K provides partial protection, but pediatric guidelines consistently recommend the shot as the preferred option.